| Trial ID: | L5771 |
| Source ID: | NCT05663515
|
| Associated Drug: |
Exenatide
|
| Title: |
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
|
| Acronym: |
EXCEED
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Pancreatic Cancer
|
| Interventions: |
DRUG: Exenatide|DRUG: Non-GLP-1 RA based glucose lowering drugs
|
| Outcome Measures: |
Primary: Incidence rate of primary diagnosis of pancreatic cancer among exenatide exposed population, To estimate the incidence rate (IR) for pancreatic cancer associated with exposure to exenatide, compared with exposure to non-GLP-1 RA based GLDs, among patients with T2DM., Follow-up starts from the index date to the study completion, an average of 1.5 years or less|Hazard ratio of primary diagnosis of pancreatic cancer among exenatide exposed population, To estimate the hazard ratio (HR) for pancreatic cancer associated with exposure to exenatide, compared with exposure to non-GLP-1 RA based GLDs, among patients with T2DM., Follow-up starts from thr index date to the study completion, an average of 1.5 years or less |
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca | Collaborators: IQVIA Pvt. Ltd
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
24000
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2024-09-30
|
| Completion Date: |
2026-03-02
|
| Results First Posted: |
|
| Last Update Posted: |
2025-04-14
|
| Locations: |
Research Site, Copenhagen, Denmark|Research Site, Helsinki, Finland|Research Site, Paris, France|Research Site, Bergen, Norway|Research Site, Barcelona, Spain|Research Site, Vänersborg, Sweden|Research Site, Edinburgh, United Kingdom|Research Site, London, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT05663515
|
